Sodium–potassium pump
Na+/K+-ATPase pump | |||||||||
---|---|---|---|---|---|---|---|---|---|
ExPASy NiceZyme view | | ||||||||
KEGG | KEGG entry | ||||||||
MetaCyc | metabolic pathway | ||||||||
PRIAM | profile | ||||||||
PDB structures | RCSB PDB PDBe PDBsum | ||||||||
|
The sodium–potassium pump (
The Na+/K+-ATPase enzyme is active (i.e. it uses energy from ATP). For every ATP molecule that the pump uses, three sodium ions are exported and two potassium ions are imported.[1] Thus, there is a net export of a single positive charge per pump cycle. The net effect is an extracellular concentration of sodium ions which is 5 times the intracellular concentration, and an intracellular concentration of potassium ions which is 30 times the extracellular concentration.[1]
The sodium–potassium pump was discovered in 1957 by the Danish scientist Jens Christian Skou, who was awarded a Nobel Prize for his work in 1997. Its discovery marked an important step forward in the understanding of how ions get into and out of cells, and it has particular significance for excitable cells such as nerve cells, which depend on this pump to respond to stimuli and transmit impulses.
All mammals have four different sodium pump sub-types, or isoforms. Each has unique properties and tissue expression patterns.[2] This enzyme belongs to the family of P-type ATPases.
Function
The Na+/K+-ATPase helps maintain resting potential, affects transport, and regulates cellular volume.[3] It also functions as a signal transducer/integrator to regulate the MAPK pathway, reactive oxygen species (ROS), as well as intracellular calcium. In fact, all cells expend a large fraction of the ATP they produce (typically 30% and up to 70% in nerve cells) to maintain their required cytosolic Na and K concentrations.[4] For neurons, the Na+/K+-ATPase can be responsible for up to 3/4 of the cell's energy expenditure.[5] In many types of tissue, ATP consumption by the Na+/K+-ATPases have been related to glycolysis. This was first discovered in red blood cells (Schrier, 1966), but has later been evidenced in renal cells,[6] smooth muscles surrounding the blood vessels,[7] and cardiac purkinje cells.[8] Recently, glycolysis has also been shown to be of particular importance for Na+/K+-ATPase in skeletal muscles, where inhibition of glycogen breakdown (a substrate for glycolysis) leads to reduced Na+/K+-ATPase activity and lower force production.[9][10][11]
Resting potential
In order to maintain the cell membrane potential, cells keep a low concentration of sodium ions and high levels of potassium ions within the cell (
Reversal potential
Even if both K+ and Na+ ions have the same charge, they can still have very different equilibrium potentials for both outside and/or inside concentrations. The sodium-potassium pump moves toward a nonequilibrium state with the relative concentrations of Na+ and K+ for both inside and outside of cell. For instance, the concentration of K+ in cytosol is 100 mM, whereas the concentration of Na+ is 10 mM. On the other hand, in extracellular space, the usual concentration range of K+ is about 3.5-5 mM, whereas the concentration of Na+ is about 135-145 mM.[citation needed]
Transport
Export of sodium ions from the cell provides the driving force for several secondary active transporters such as membrane transport proteins, which import glucose, amino acids and other nutrients into the cell by use of the sodium ion gradient.
Another important task of the Na+-K+ pump is to provide a Na+ gradient that is used by certain carrier processes. In the
Controlling cell volume
Failure of the Na+-K+ pumps can result in swelling of the cell. A cell's
Functioning as signal transducer
Within the last decade[
Protein-protein interactions play a very important role in Na+-K+ pump-mediated signal transduction. For example, the Na+-K+ pump interacts directly with
Controlling neuron activity states
The Na+-K+ pump has been shown to control and set the intrinsic activity mode of
Mechanism
Looking at the process starting from the interior of the cell:
- The pump has a higher affinity for Na+ ions than K+ ions, thus after binding ATP, binds 3 intracellular Na+ ions.[3]
- ATP is aspartate residue and subsequent release of ADP. This process leads to a conformational change in the pump.
- The conformational change exposes the Na+ ions to the extracellular region. The phosphorylated form of the pump has a low affinity for Na+ ions, so they are released; by contrast it has high affinity for the K+ ions.
- The pump binds 2 extracellular K+ ions, which induces dephosphorylation of the pump, reverting it to its previous conformational state, thus releasing the K+ ions into the cell.
- The unphosphorylated form of the pump has a higher affinity for Na+ ions. ATP binds, and the process starts again.
Regulation
Endogenous
The Na+/K+-ATPase is upregulated by cAMP.[28] Thus, substances causing an increase in cAMP upregulate the Na+/K+-ATPase. These include the ligands of the Gs-coupled GPCRs. In contrast, substances causing a decrease in cAMP downregulate the Na+/K+-ATPase. These include the ligands of the Gi-coupled GPCRs. Note: Early studies indicated the opposite effect, but these were later found to be inaccurate due to additional complicating factors.[citation needed]
The Na+/K+-ATPase is endogenously negatively regulated by the inositol pyrophosphate 5-InsP7, an intracellular signaling molecule generated by IP6K1, which relieves an autoinhibitory domain of PI3K p85α to drive endocytosis and degradation.[29]
The Na+/K+-ATPase is also regulated by reversible phosphorylation. Research has shown that in estivating animals, the Na+/K+-ATPase is in the phosphorylated and low activity form. Dephosphorylation of Na+/K+-ATPase can recover it to the high activity form.[13]
Exogenous
The Na+/K+-ATPase can be pharmacologically modified by administering drugs exogenously. Its expression can also be modified through hormones such as triiodothyronine, a thyroid hormone.[13][30]
For instance, Na+/K+-ATPase found in the membrane of heart cells is an important target of cardiac glycosides (for example digoxin and ouabain), inotropic drugs used to improve heart performance by increasing its force of contraction.
Muscle contraction is dependent on a 100- to 10,000-times-higher-than-resting intracellular Ca2+ concentration, which is caused by Ca2+ release from the muscle cells' sarcoplasmic reticulum. Immediately after muscle contraction, intracellular Ca2+ is quickly returned to its normal concentration by a carrier enzyme in the plasma membrane, and a calcium pump in sarcoplasmic reticulum, causing the muscle to relax.
According to the Blaustein-hypothesis,
Pharmacological regulation
In certain conditions such as in the case of cardiac disease, the Na+/K+-ATPase may need to be inhibited via pharmacological means. A commonly used inhibitor used in the treatment of cardiac disease is digoxin (a cardiac glycoside) which essentially binds "to the extracellular part of enzyme i.e. that binds potassium, when it is in a phosphorylated state, to transfer potassium inside the cell"[36] After this essential binding occurs, a dephosphorylation of the alpha subunit occurs which reduces the effect of cardiac disease. It is via the inhibiting of the Na+/K+-ATPase that sodium levels will begin to increase within the cell which ultimately increases the concentration of intracellular calcium via the sodium-calcium exchanger. This increased presence of calcium is what allows for the force of contraction to be increased. In the case of patients where the heart is not pumping hard enough to provide what is needed for the body, use of digoxin helps to temporarily overcome this.
Discovery
Na+/K+-ATPase was proposed by
In 1997, he received one-half of the Nobel Prize in Chemistry "for the first discovery of an ion-transporting enzyme, Na+,K+-ATPase."[38]
Genes
- Alpha: . ATP1A1 is expressed ubiquitously in vertebrates, and ATP1A3 in neural tissue. ATP1A2 is also known as "alpha(+)". ATP1A4 is specific to mammals.
- Beta: ATP1B1ATP1B1, ATP1B2, ATP1B3ATP1B3, ATP1B4
The parallel evolution of resistance to cardiotonic steroids in many vertebrates
Several studies have detailed the evolution of cardiotonic steroid resistance of the alpha-subunit gene family of Na/K-ATPase (ATP1A) in vertebrates via amino acid substitutions most often located in the first extracellular loop domain.[39][40][41][42][43][44][45] Amino acid substitutions conferring cardiotonic steroid resistance have evolved independently many times in all major groups of tetrapods.[43] ATP1A1 has been duplicated in some groups of frogs and neofunctionlised duplicates carry the same cardiotonic steroid resistance substitutions (Q111R and N122D) found in mice, rats and other muroids.[46][39][40][41]
In insects
In Drosophila melanogaster, the alpha-subunit of Na+/K+-ATPase has two paralogs, ATPα (ATPα1) and JYalpha (ATPα2), resulting from an ancient duplication in insects.[47] In Drosophila, ATPα1 is ubiquitously and highly expressed, whereas ATPα2 is most highly expressed in male testes and is essential for male fertility. Insects have at least one copy of both genes, and occasionally duplications. Low expression of ATPα2 has also been noted in other insects. Duplications and neofunctionalization of ATPα1 have been observed in insects that are adapted to cardiotonic steroid toxins such as cardenolides and bufadienolides.[47][48][49][50][51] Insects adapted to cardiotonic steroids typically have a number of amino acid substitutions, most often in the first extra-cellular loop of ATPα1, that confer resistance to cardiotonic steroid inhibition.[52][53]
See also
- Sodium-calcium exchanger
- Thyroid hormone
- V-ATPase
References
- ^ PMID 33716756.
- PMID 28634454.
- ^ ISBN 978-0-7216-0240-0.
- ISBN 978-0-470-57095-1.
- PMID 22434069.
- S2CID 22543559.
- PMID 3030131.
- S2CID 25076348.
- S2CID 2291836.
- S2CID 195329741.
- S2CID 209317559.
- PMID 12730376.
- ^ S2CID 39271006.
- PMID 15975899.
- PMID 16267270.
- PMID 19506077.
- PMID 11139403.
- PMID 23284664.
- PMID 26674618.
- PMID 28970791.
- PMID 25566080.
- PMID 15260948.
- PMID 21297628.
- PMID 25928094.
- ^ Forrest M (4 April 2015). "The Neuroscience Reason We Fall Over When Drunk". Science 2.0. Retrieved 30 May 2018.
- S2CID 14658965.
- PMID 34161264.
- ISBN 978-0-8493-3978-3.
- S2CID 226036261.
- PMID 9031683.
- S2CID 9814212.
- PMID 18556748.
- PMID 20211726.
- S2CID 20180376.
- S2CID 2066801.
- ^ "Na+/K+-ATPase and inhibitors (Digoxin)". Pharmacorama. Archived from the original on 2020-09-28. Retrieved 2019-11-08.
- S2CID 32516710.
- ^ "The Nobel Prize in Chemistry 1997". NobelPrize.org. Nobel Media AB. 15 October 1997.
- ^ PMID 19465576.
- ^ a b Hernández Poveda M (2022) Convergent evolution of neo-functionalized duplications of ATP1A1 in dendrobatid and grass frogs. MS Thesis Dissertation. Universidad de los Andes
- ^ PMID 33887183.
- PMID 26905927.
- ^ PMID 35972957.
- PMID 36472530.
- PMID 23289579.
- PMID 2853965.
- ^ PMID 23019645.
- PMID 31154978.
- S2CID 3908073.
- PMID 36945443.
- PMID 36945443.
- PMID 12949136.
- PMID 22826239.
External links
- Sodium,+Potassium+ATPase at the U.S. National Library of Medicine Medical Subject Headings (MeSH)
- RCSB Protein Data Bank: Sodium–Potassium Pump
- A video by Khan Academy.